Editorial: choosing the optimal screening method for latent TB in patients with IBD commencing anti-TNF-therapy-authors' reply

Aliment Pharmacol Ther. 2022 May;55(10):1348-1349. doi: 10.1111/apt.16918.
No abstract available

Publication types

  • Editorial
  • Comment

MeSH terms

  • Adalimumab
  • Humans
  • Inflammatory Bowel Diseases* / diagnosis
  • Inflammatory Bowel Diseases* / drug therapy
  • Infliximab
  • Latent Tuberculosis* / diagnosis
  • Latent Tuberculosis* / drug therapy
  • Tumor Necrosis Factor Inhibitors* / therapeutic use

Substances

  • Tumor Necrosis Factor Inhibitors
  • Infliximab
  • Adalimumab